Last reviewed 2026-04-19 · How we verify

Part A: AZD8186 monotherapy

AstraZeneca · Phase 1 active Small molecule

Part A: AZD8186 monotherapy is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.

At a glance

Generic name	Part A: AZD8186 monotherapy
Sponsor	AstraZeneca
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

AZD8186 First Time In Patient Ascending Dose Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Part A: AZD8186 monotherapy CI brief — competitive landscape report
Part A: AZD8186 monotherapy updates RSS · CI watch RSS
AstraZeneca portfolio CI

Frequently asked questions about Part A: AZD8186 monotherapy

What is Part A: AZD8186 monotherapy?

Part A: AZD8186 monotherapy is a Small molecule drug developed by AstraZeneca.

Who makes Part A: AZD8186 monotherapy?

Part A: AZD8186 monotherapy is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What development phase is Part A: AZD8186 monotherapy in?

Part A: AZD8186 monotherapy is in Phase 1.

Manufacturer: AstraZeneca — full pipeline
Compare: Part A: AZD8186 monotherapy vs similar drugs
Pricing: Part A: AZD8186 monotherapy cost, discount & access